Trovagene (TROV) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Trovagene, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results
March 12, 2015 4:05 PM EDTSAN DIEGO, March 12, 2015 /PRNewswire/ --Â Trovagene, Inc. (NASDAQ:Â TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the fourth quarter and full year ended December 31, 2014.
"We are releasing significant clinical data demonstrating that our molecular diagnostic platform is able to detect and monitor driver mutations in highly prevalent cancer types. Our assays provide critical information to oncologists to track the dynamic changes of a patient's tumor and their response to treatment at the genetic level," stated Antonius Schuh, Ph.D.,... More
